Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Shire recalls ADHD drug patches
Drug patches have had a tough time lately, with recalls coming on everything from too-tight adhesive to slits in active-ingredient reservoirs. Today, the recalled patch in the news is Shire's Daytrana, an attention deficit hyperactivity disorder med. Two lots were withdrawn on concerns about the patch's liner, which could be difficult for patients to remove before applying the patch. Shire recalled a limited number of patches for the same reason just a year ago.
Shire sells the patches on license from Noven Pharmaceuticals, which sent out a statement saying that it has identified the "definitive root cause" of the defect and is now "aggressively testing potential solutions."
- read the Associated Press article
Related Articles:
Another company recalls fentanyl patch
Mylan steps into pain-patch void
AHA: Kids need EKG before ADHD meds
FDA approves Lilly's ADHD drug Strattera
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


